Research Spotlight from The FASEB Journal: Toward Personalized Therapies for Rare Neurological Disorders
Thursday, January 29, 2026Patients with CaV2.1 channelopathies face severe and often debilitating symptoms, such as seizures, migraines, tremors, and developmental delays. Although some symptoms overlap among these rare neurological conditions, patients often have different underlying mutations. In a recent study published in The FASEB Journal, researchers report the effects of two human CaV2.1 channelopathy mutations in a rat model, the findings of which could result in personalized therapies.
The CaV2.1 channel is a voltage-gated calcium channel in neurons that opens in response to an action potential to let calcium into the cell. When calcium ions enter, they trigger the release of neurotransmitters that can change how other neurons function. The calcium channel is composed of a main pore-forming protein called the α1A subunit, in addition to several auxiliary subunits. The CACNA1A gene encodes the α1A subunit and mutations in this gene cause a range of CaV2.1 channelopathies. Patients with these disorders can have similar symptoms, but sequencing studies show that patients often have different mutations in CACNA1A that result in distinct defects in channel function. Current treatments, however, only manage symptoms—there are no cures that fix the underlying defects.
Determining the effects of specific CACNA1A mutations on the α1A subunit could point the way toward individualized treatments that could help fix channel function. To do this, Roger Bannister, Ulises Meza, Michael Wangler, Jose-Manuel Perez-Aguilar, and colleagues at several universities in the U.S., Germany, and Mexico studied the effects of mutations in two CaV2.1 channelopathy patients with epilepsy.
The two human mutations studied are in the domain of the α1A subunit that senses the voltage changes of an action potential. The researchers made those mutations in the analogous locations of the rat α1A subunit and expressed these mutants in a cell line in vitro. In patch-clamp experiments, the mutations showed distinct differences in how the channel responded to voltage changes, affecting how quickly it opened and closed compared to the wild-type subunit. Computer simulations revealed that the two mutations made the α1A subunit more rigid in different, but nearby, regions of the protein, which could help explain the mutations’ effects on channel movement.
“Our results demonstrate that although different mutations may produce similar clinical features, they do not necessarily alter CaV2.1 channel function in the same way,” says Meza. “This functional diversity helps explain the differences in severity and progression observed among affected individuals and can help us move closer to designing personalized therapies that match the specific needs of each patient.”
Funding: National Institute of Neurological Disorders and Stroke; National Ataxia Foundation; Consejo Potosino de Ciencia y Tecnología; National Institutes of Health Medical Scientist Training Program Training Grant; and Secretaría de Ciencia, Humanidades, Tecnología e Innovación
Read the full article, “Altered gating of two CaV2.1 variants linked to neurodevelopmental disorders with epilepsy and migraine,” published in The FASEB Journal.